MONDAY, May 14, 2018 -- The U.S. Food and Drug Administration has expanded its approval of the multiple sclerosis drug Gilenya (fingolimod) to include children aged 10 and older.
It's the first multiple sclerosis drug approved for children, the agency said in a news release. The drug was approved in 2010 to treat adults with relapsing MS.